Investment
Anticipating a Series A round in Q2 2025
Limula is seeking conversations with Series A investors, to establish relationships and build trust ahead of the next financing round.
- Early stage.
- Biotech and Pharma
CEO
Limula
Epalinges, Switzerland
Trained as a chemist (DPhil from University of Oxford), I co-founded Limula in 2020 and raised over CHF 20m to build a stellar team and develop a product
My organisation
Limula is a Life Science Tools company based in Lausanne, Switzerland, addressing a key bottleneck of one of the fastest growing therapeutic modality: Cell & Gene Therapy. Limula proprietary technology enables on-demand and at-scale manufacturing of highly-personalised treatments in a single device, using end-to-end automation and integrated process analytics.
10:15 - 11:20
Experience the forefront of healthtech innovation at EPFL Investor Day!
Investment
Anticipating a Series A round in Q2 2025
Limula is seeking conversations with Series A investors, to establish relationships and build trust ahead of the next financing round.